Perspectives on Enquiry & Evidence

Cytel's blog featuring the latest industry insights.

FDA Increases Calls for Manufacturers to Ensure Trial Diversity, but Does It Fall Short of Addressing Health Inequalities in Product Development?

The evidence is staggering on the unequal health burdens experienced by specific patient groups defined by ethnic, gender, or socioeconomic risk factors and the different health outcomes these groups may have in clinical trials. And while efforts have been made to address these inequalities, they are still falling short.

Read full article

Clear Filters

Filter by

October 3, 2022

Bayesian Methods for Historical Borrowing: Conjugate Priors

The wider availability of electronic health data, medical registries, and even larger proprietary datasets means that..

Read article

June 22, 2022

How to Determine if Your Clinical Trial Has Sufficient Data?

It can be difficult to estimate just how much time and data you need to address the multitude of considerations that..

Read article

March 23, 2022

How to Use Historical Data to Mitigate Clinical Trial Risk

For over a decade, the number one reason cited for trial discontinuity has been challenges associated with recruitment..

Read article

September 15, 2021

A Bayesian Optimal Design Advancing the Precision Medicine Approach

There is recognized heterogeneity within any given tumor‐type from patient to patient (inter‐patient heterogeneity),..

Read article

July 2, 2021

Use of Rolling-enrollment Designs to Accelerate Clinical Trials

Popular statistical designs, such as CRM (O’Quigley et al., 1990), mTPI-2 (Guo et al., 2017), and i3+3 (Liu et al.,..

Read article

May 28, 2021

Use of Bayesian Approach in Basket Trial Design

Advancements in biomarkers and momentum in precision medicine has paved the foundation for complex studies like basket..

Read article

March 5, 2021

Single Arm Multi-Stage Phase 2 Cancer Trials

Early stage Phase 2 clinical trials are often designed as multi-stage single arm trials, which quickly identify..

Read article

February 18, 2021

Introduction to Evidence Synthesis and Bayesian dynamic borrowing

In the last few years, there has been a growing interest in historical borrowing or augmented trials. There is an..

Read article

January 26, 2021

Cytel Thought Leadership on Power of Bayesian Methods

Bayesian models offer a flexible way of incorporating historical controls in the analysis of trial data (whether single..

Read article

October 5, 2020

The Meta-Analytic-Predictive Priors Generation and Comparisons

Staying abreast of the rapid pace of clinical development means adopting innovative or computationally intensive..

Read article

May 19, 2014

Frequentist? Time for an update!

Pantelis Vlachos, PhD, is a Director at Cytel Consulting. He works with a team of experts who regularly assist clinical..

Read article

Therapeutics Development Team

Software

Innovative Trial Design

RWE

HEOR

Biometrics Implementation

Functional Service Provision

CDI

Events

Newsroom

Resources

Perspectives on Enquiry & Evidence

FDA Increases Calls for Manufacturers to Ensure Trial Diversity, but Does It Fall Short of Addressing Health Inequalities in Product Development?

Subscribe to our weekly newsletter